BCL2 and neoplasm: With consistent to the above findings, immunohistochemistry analysis of tumor tissue treated with Aea4 or Aea25 revealed that inhibition of FGFR1 produces a subsequent reduction in phosphorylation of ERK/Akt and the anti-apoptotic protein Bcl-2, indicating that the apoptotic effects of Aea4 or Aea25 treatment result directly from an inhibition of the cell survival pathway regulated by the FGFR1.